Compare BLDP & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLDP | QURE |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | Canada | Netherlands |
| Employees | N/A | 248 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 592.5M | 663.4M |
| IPO Year | 2009 | 2013 |
| Metric | BLDP | QURE |
|---|---|---|
| Price | $2.37 | $15.59 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 7 | 14 |
| Target Price | $2.24 | ★ $45.42 |
| AVG Volume (30 Days) | 2.7M | ★ 4.7M |
| Earning Date | 01-01-0001 | 06-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $41.84 | $126.14 |
| Revenue Next Year | $14.68 | $395.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $7.76 |
| 52 Week High | $4.10 | $71.50 |
| Indicator | BLDP | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 58.73 | 43.09 |
| Support Level | $1.79 | $13.29 |
| Resistance Level | $2.92 | $16.62 |
| Average True Range (ATR) | 0.13 | 2.08 |
| MACD | 0.05 | 0.25 |
| Stochastic Oscillator | 64.49 | 41.74 |
Ballard Power Systems Inc is engaged in design, development, manufacture, sale and service of proton exchange membrane ("PEM") fuel cell products for a variety of applications, focusing on power products for bus, truck, rail, marine, stationary and emerging market (material handling, off-road and other) applications, as well as the delivery of services, including technology solutions, after sales services and training. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. Key geographical revenue is derived from Poland followed by United States, United Kingdom, and other countries.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.